Elenestinib Clinical Trials
2 recruitingDrug
Phase 21Phase 31Phase 11
Showing 1–2 of 2 trials
Recruiting
Phase 2Phase 3
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Indolent Systemic MastocytosisSmoldering Systemic Mastocytosis
Blueprint Medicines Corporation534 enrolled64 locationsNCT04910685
Recruiting
Phase 1
A Study of Elenestinib in Healthy Adult Female Participants
Healthy Participants
Blueprint Medicines Corporation20 enrolled1 locationNCT07388511